期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 66, 期 7, 页码 4703-4733出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01817
关键词
-
Proteolysis targeting chimeras (PROTACs) recruit E3 ubiquitin ligases to degrade disease-causing proteins. Heterobifunctional PROTACs consisting of an IAP antagonist linked to von Hippel-Lindau or cereblon ligands effectively deplete cellular IAPs. These compounds show superior inhibition of cancer cell viability compared to antagonists and provide valuable tools for studying the biological roles of IAPs and E3 targeting therapies.
Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via recruiting E3 ubiquitin ligases, which enable the transfer of ubiquitin tags onto their target proteins, leading to proteasomal degradation. However, several E3 ligases are validated pharmacological targets themselves, of which inhibitor of apoptosis (IAP) proteins are considered druggable in cancer. Here, we report three series of heterobifunctional PROTACs, which consist of an IAP antagonist linked to either von Hippel-Lindau-or cereblon-recruiting ligands. Hijacking E3 ligases against each other led to potent, rapid, and preferential depletion of cellular IAPs. In addition, these compounds caused complete X-chromosome-linked IAP knockdown, which was rarely observed for monovalent and homobivalent IAP antagonists. In cellular assays, hit degrader 9 outperformed antagonists and showed potent inhibition of cancer cell viability. The hetero-PROTACs disclosed herein are valuable tools to facilitate studies of the biological roles of IAPs and will stimulate further efforts toward E3 targeting therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据